Jonathan Pritz is a GentiBio Board Observer and an Analyst at RA Capital. In addition to GentiBio, he is a Board Observer at Hyku Biosciences and Capstan Therapeutics. Jonathan holds a BS in Microbiology and Cell Science from the University of Florida and a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University.
Jonathan Pritz, PhD
Analyst, RA Capital, Board Observer
